医学
祖细胞
干细胞
间充质干细胞
严重肢体缺血
血运重建
治疗性血管生成
再生(生物学)
临床试验
骨髓
血管生成
干细胞疗法
内皮祖细胞
病理
内科学
新生血管
生物
心肌梗塞
细胞生物学
作者
Yasuyuki Fujita,Atsuhiko Kawamoto
标识
DOI:10.1016/j.addr.2017.09.001
摘要
Chronic critical limb ischemia (CLI) represents an end-stage manifestation of peripheral arterial disease (PAD). CLI patients are at very high risk of amputation and cardiovascular complications, leading to severe morbidity and mortality. Because many patients with CLI are ineligible for conventional revascularization procedures, it is urgently needed to explore alternative strategies to improve blood supply in the ischemic tissue. Although researchers initially focused on gene/protein therapy using proangiogenic growth factors/cytokines, recent discovery of somatic stem/progenitor cells including bone marrow (BM)-derived endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) has drastically developed the field of therapeutic angiogenesis for CLI. Overall, early phase clinical trials demonstrated that stem/progenitor cell therapies may be safe, feasible and potentially effective. However, only few late-phase clinical trials have been conducted. This review provides an overview of the preclinical and clinical reports to demonstrate the usefulness and the current limitations of the cell-based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI